Skip to main content

Exploring the aggressiveness of prostate cancer to enable an individualised treatment approach

Ziel

Prostate cancer is the most frequently diagnosed malignancy in the western male population and the associated socio-economic impact on healthcare is more than worrying. There is one key feature of confined (stage T2) prostate cancer that needs to be addressed with immediate urgency: its true aggressiveness. Not all cancers are life threatening and early diagnosis, although needed to improve outcome, will lead to overtreatment of patients with indolent prostate cancer resulting in unnecessary treatment-related morbidity. Therefore, methods to identify clinically significant forms of prostate cancer have to be developed. To pursue this, the initial assessment of the extent of the disease process (clinical staging) needs to be adequate. Obtaining pre-treatment representative tumor tissue (biopsies) is a major clinical challenge, as the disease is often multi-focal and heterogeneous. Accurate functional in vivo imaging modalities could guide these biopsies. Modern genomics technologies have identified numerous cancer cell-associated genetic markers being expressed in prostate cancer tissue or body fluids. Closing the gap between genomics and a non-invasive metabolic assessment of the in vivo prostate, we propose to identify new in vivo targets/biomarkers indicating confined prostate cancer aggressiveness with the underlying central hypothesis: early functional metabolic differences in different tumor foci determine whether it will grow into life-threatening prostate cancer or not. To track these early metabolic differences, the very latest magnetic resonance methodologies, including 13C MR of hyperpolarized metabolites and 1H- and 31P-MRSI of the in vivo human prostate at a field strength of 7 Tesla, will be further developed and implemented. In the well-established translational research environment at the host institution, potential new biomarkers translate into molecular diagnostics or imaging tools for an accurate individual assessment of cancer aggressiveness.

Wissenschaftliches Gebiet

  • /Medizin- und Gesundheitswissenschaften/Klinische Medizin/Onkologie/Krebs/Prostatakrebs

Aufforderung zur Vorschlagseinreichung

ERC-2009-StG
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

ERC-SG - ERC Starting Grant
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Gastgebende Einrichtung

STICHTING KATHOLIEKE UNIVERSITEIT
Adresse
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Niederlande
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 1 800 209
Hauptforscher
Thomas Wilhelmus Jacobus Scheenen (Dr.)
Kontakt Verwaltung
Wim Van Oijen (Mr.)

Begünstigte (1)

STICHTING KATHOLIEKE UNIVERSITEIT
Niederlande
EU-Beitrag
€ 1 800 209
Adresse
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Aktivitätstyp
Higher or Secondary Education Establishments
Hauptforscher
Thomas Wilhelmus Jacobus Scheenen (Dr.)
Kontakt Verwaltung
Wim Van Oijen (Mr.)